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Japanese Pharmaceuticals and Medical Devices Agency (PMDA) websites. Relevant 
drugs were defined as related to the treatment of neoplasms, according to the World 
Health Organisation International Classification of Diseases Version 2010. Results: 
The FDA approved a total of 55 cancer drugs between 2004 and 2013 compared to 
45 by the PMDA, of which 24 drugs were approved by both organisations. Although 
less than half of currently FDA-approved cancer drugs are approved by the PMDA, 
87.5% of drugs approved by the FDA between 2004 and 2007 have subsequently been 
approved by the PMDA with an average delay of 2.95 years. Of the total number of 
drugs for all indications, 21% of FDA-approved drugs and 16% of PMDA-approved 
drugs were indicated for oncology. Although the proportion of drugs focused on 
breast cancer, lymphoma and bone marrow disorders were similar between the 
two organisations; the FDA had a higher proportion of drugs indicated for leuke-
mias and prostate cancer, whilst the PMDA had a larger focus on colorectal cancer 
drugs. ConClusions: From the analysis presented here, there are clear differ-
ences between cancer drug approval in Japan and the USA with regards to time-to-
approval of new drugs, as well as the specific treatment areas for which new drugs 
have been submitted.
PCN40
ChaNge iN PerCeNtage of Left VeNtriCuLar ejeCtioN fraCtioN iN 
Breast CaNCer PatieNts reCeiVed trastuzumaB treatmeNt
Areepium N
Chulalongkorn University, Bangkok, Thailand
objeCtives: To review prevalence and risk factors of trastuzumab’s cardiotoxic 
effects in breast cancer patients. Methods: Retrospective chart review of 20 cases 
recieved trastuzumab for breast cancer treatment at Phramongkutklao hospital dur-
ing 2010-2011. Results: Average age of patients in this study was 58.2 +/- 9.3 years 
old. The most common stage of breast cancer were stage III (11/20, 55%). Average 
cycle per patients was 21.3 +/- 10.1. There were 12 patients (60%) completed 1 year 
course of treatment, 7 patients still recieving the treatment and 1 patient had to 
discontinue treatment before completion. There were 13 patients (65%) had declin-
ing in percentage of left ventricular ejection fraction after trastuzumab treatment, 6 
(46%) patients had less than 10% declining of left ventricular ejection fraction, equal 
to number of patients with 11-20% declining of left ventricular ejection fraction (6 
out of 12, 50%). In this study, we found 1 patients who had to discontinue treatment 
due to over 20% declining of ejection fraction. Due to the small number of cases, 
we did not found any statistical significant for the risk factors associated with the 
declining in ejection fraction among patients recieved trastuzumab treatment in 
this study. ConClusions: Cardiotoxicy in term of declining in percentage of left 
ventricular ejection fraction was not uncommon among breast cancer treated with 
trastuzumab. Closely monitoring patients with schedule echocardiogram is war-
ranted for safety use of this drug.
PCN41
CaNCer treatmeNt iN ChiNa: hoW are PoLiCY aNd PraCtiCe iN tier 
1 Versus tier 2/3 Cities imPaCtiNg PatieNt aCCess to high-Cost 
theraPies
Zhou M, Ng KF
Decision Resources Group, Hong Kong, China
objeCtives: The Chinese oncology market is increasingly important to multina-
tional and local pharmaceutical companies. However, access to high-cost medicines 
is fragmented within China. This study explored current prescribing and reimburse-
ment of high-cost, targeted therapies and differences between Tier 1 and Tier 2/3 
cities. Methods: Some 76 oncologists from different tier cities were surveyed 
regarding their current and expected future prescribing for gastric cancer (GC) and 
hepatocellular carcinoma (HCC). In addition, payers who influence reimbursement 
at national and/or regional levels were interviewed. Results: Chemotherapy still 
dominates GC and HCC treatment in China, with limited use of high-cost targeted 
therapies; reimbursement is considered the greatest barrier to accessing targeted 
therapies. Almost 60% of HCC patients do not receive sorafenib due to cost/reim-
bursement-related reasons. Patient assistance programs and private insurance 
schemes, along with government initiatives such as negotiation for selective pro-
vincial formularies inclusion and “disastrous diseases” coverage will help break this 
barrier. Patient share of high-cost GC and HCC therapies is expected to double over 
the next three years. We also found disparity in access to cancer therapies between 
different tier cities. More patients in Tier 1 cities have urban resident basic medical 
insurance than in Tier 2/3 cities (34% versus 24%). In Tier 1 cities, relatively more 
patients receive targeted therapy (23% versus 16%), compared with Tier 2/3 cities. 
Another compounding factor is that the cost of these therapies is lower in Tier 1 cit-
ies than in most Tier 2/3 cities (trastuzumab costs $1800 per cycle in Shanghai versus 
$2500 in Shijiazhuang). ConClusions: There is huge opportunity for high-cost 
cancer therapies in China; however, uneven reimbursement between cities means 
local market access strategies are required to maximize patient share.
PCN42
iN Vitro drug reLease aNd ex ViVo PermeatioN studY of PrePared 
mouth dissoLViNg taBLets of fLuCoNazoLe through PorCiNe  
BuCCaL muCosa
Chakraborty T, Saini V
Maharishi Markandeshwar University, Ambala Haryana, India
objeCtives: Aim of the study was concerned with formulation and evaluation of 
mouth dissolving tablets. Fluconazole is a broad spectrum triazole derivative useful 
in treatment of oropharyngeal and esophageal candidiasis, but it is poorly water 
soluble drug, for that an attempt was made to form complex with β -Cyclodextrin 
to make it water soluble and then deliver via buccal mucosa. Methods: The tab-
lets were prepared by wet granulation method using permeation enhancer and 
solubilizing agent β -Cyclodextrin and other excipients using 32 factorial designs. 
The amount of drug in each tablet was 50 mg and average weight of each tablet 
was found to be 230 mg. The prepared tablets were evaluated and compared in 
vey was conducted in 87 cervical cancer patients admitted to Dr. Sardjito Hospital, 
a referral hospital in Yogyakarta Province-Indonesia, between June to December 
2013. Data on HRQOL was collected using EQ-5D-3L (Indonesian version). As no 
Indonesian-EQ-5D-3L value set exists, Malaysian value set was used to calculate 
utility among these patients. Results: About 14%, 51%, 31% and 5% of patients 
were in stage I to IV, respectively. The most frequently reported problems were pain/
discomfort (67.82%) and anxiety/depression (57.47%). The mean of EQ-5D VAS score 
was 75.83 (SD= 17.03). The mean utility value was 0.830 (SD= 0.182), 0.751 (SD= 0.188), 
0.704 (SD= 0.205), and 0.766 (SD= 0.131) for patients with stage I to IV, respectively. 
Based on the stage of cervical cancer, the proportion of patients reporting problems 
in each dimension tended to increase from stage I to stage IV while the EQ-5D VAS 
score tended to decrease from stage I to stage IV. The utility value also tended to 
decrease from stage I to stage III, however it rather increased for patients with stage 
IV. ConClusions: Cervical cancer significantly affects patient’s HRQOL. Effort 
should be made to improve the quality of life of cervical cancer patients especially 
in term of pain /discomfort and anxiety/depression reduction.
CaNCer – health Care use & Policy studies
PCN37
iNsuraNCe CoVerage PoLiCies for ComPaNioN diagNostiCs iN  
Breast CaNCer
Jha RK, Singh A, Kapoor A, Gupta J
Optum Global Solutions, Noida, India
objeCtives: Personalized medicine along with successful delivery of novel diag-
nostics has potential to revolutionize the patient care. However, the major challenge 
includes reimbursement system, specifically in obtaining coverage, appropriate 
coding, and value-based payment for diagnostics. To determine the coverage poli-
cies, extent of the tests covered and evidence basis for the coverage decisions by 
U.S. payers for genomic tests in breast cancer. Methods: We reviewed the cover-
age policies for genomic tests in breast cancer, coverage extent, and evidence for 
coverage decisions. An online search of top US insurers was conducted in January 
2014 to identify the coverage policies for genomic tests. In addition to FDA approval, 
the coverage policy and assessments were also reviewed. Results: In this search 
of insurance companies, 22 coverage policies for genomic testing were identified. 
Coverage determinations were made for 5 unique tests for disease diagnosis, prog-
nosis and risk assessment in the 22 policies analyzed. For genomic tests in Breast 
Cancer, one of the 5 tests was approved by the FDA and covered by only one insurer 
that issued a coverage decision on it. Coverage policies specific to disease-related 
genomic tests varied across the insurance companies that were evaluated. The 
Oncotype Dx is covered by all insurers to assess breast cancer recurrence risk, 
but considered investigational. Only 2 diagnostic tests were covered by atleast one 
insurer, however one of the tests was reviewed and covered by all insurers. Humana 
covered two tests; Mammaprint and Oncotype DX. The Mammaprint test for breast 
cancer risk recurrence had discordant coverage policies among tests reviewed by 
more than one insurer. ConClusions: Although some insurers are willing to pro-
vide coverage based on limited evidence of clinical utility, insurance coverage for 
genomic testing is low and variable. This is likely due to few studies published 
that demonstrate clinical utility and availability of alternative screening methods.
PCN38
eCoNomiC imPaCt of geNetiC diagNostiC test for Breast CaNCer - 
heaLth teChNoLogY assessmeNt iN sLoVak heaLth Care eNViroNmeNt
Mesaros T1, Mesarosova A2, Kucharovic B3
1University of Economics in Bratislava, Bratislava, Slovak Republic, 2SMs CONSULTING, Ltd., 
Bratislava, Slovak Republic, 3Xeneo Slovakia, Ltd., Pezinok, Slovak Republic
objeCtives: To explore the effects of genetic testing of patients with breast cancer by 
Oncotype DX for decision of further therapy and their prognosis. Methods: Health 
economy model, using Cost-Utility Analysis (CUA), complemented by Budget-Impact 
Analysis (BIA) on public health insurance coverage in Slovakia. Markov Model (life 
time horizon) for BC patient management was developed, comparing diagnosis by 
Oncotype DX and standard diagnostic methods. Outcomes observed were decreased 
by number of women with chemotherapy (CT) and increased by proportion of women 
with hormonal treatment alone (HT) and their Recurence Score (RS, observed from 
test) in horizon of 10 years. Payer perspective and direct health care costs only, asso-
ciated with breast cancer diagnoses patient management were considered in CUA 
and BIA for diagnosis subgroups. Discount rate of 5% was used for costs as well as 
outcomes. Sensitivity analysis for major complications was implemented. Results: 
CUA for Oncotype DX vs. standard care associated with decreased proportion of CT 
and increased proportion of HT with cost per QALY 12 889 € and cost per LY 11 019 € . 
Net costs (BIA) associated with Oncotype DX for cohort of patients 1 200 are 3.92 mil. 
€ . ConClusions: Oncotype DX is considered cost-effective in terms of diagnoses 
and followed treatment of breast cancer patients. Oncologists are able to differentiate 
between a low or intermediate RS and a high RS using standard prognostic criteria. 
Provision of the actual RS changed the treatment recommendations in nearly 40% of 
cases, suggesting that the RS may reduce chemotherapy use.
PCN39
the differeNCes BetWeeN CaNCer drug aPProVaLs iN jaPaN aNd  
the usa
Anderson R1, Brooks-Rooney C2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Singapore Pte Ltd., Singapore
objeCtives: Cancer is amongst the leading causes of death globally and was 
responsible for a total of 8.2 million deaths worldwide in 2012. The aim of this 
study was to investigate the similarities and differences between the approval of 
new molecular entities and biologics for the treatment of cancers in Japan and the 
USA. Methods: Drugs approved from 2004 to 2013 were identified through publi-
cally available reports on the USA Food and Drug Administration (FDA) and the 
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tient stay were linked. Their overall survival data were presented as product-limit 
survival probabilities. Results: There were 240 to 290 new cases annually between 
2006 and 2011. The raw incidence rate was about 1.1 to 1.26 per 100,000 persons,. 
The age adjusted incidence rate was around 1.5 per 100,000 persons. This was much 
lower than that the overall incidence in the US (21.1 per 100,000 per year). But it was 
similar to that of Asia-Pacific islanders in the US. The proportion of death between 
2006 and 2011 were 28.8% and 21.9% among males and females respectively. This 
was different from the US population, whose 5 year survival was 91.3%. The popula-
tion composition of the US was different from that in Taiwan and thus cannot be 
compared directly. About 29% of Taiwan patients were farmers. The mortality of 
farmers (36.5%) was slightly higher than that of non-farmers (22.4%). After control-
ling for age and sex, the hazard ratio of farmer vs. non-farmers was 1.136. Their age 
of diagnosis was much higher than the non-farmers: 82% and 34% for farmers and 
non-farmers diagnosed at age 65 and above, respectively. ConClusions: Malignant 
melanoma is found to be a rare but deadly disease in Taiwan. One reason for low 
survival probability was that farmers delayed the diagnosis to old age. It is suggested 
to screen farmers in early age.
PCN47
hoW siNgLe arm Phase ii data CaN suPPort reimBursemeNt for 
oNCoLogiCs iN austraLia
Macaulay R
HERON Commercialization, London, UK
objeCtives: The Food and Drug Administration (FDA) have approved 28 oncolog-
ics across 37 indications on the basis of pivotal Phase II data lacking an active 
comparator (Macaulay, ISPOR Toronto 2014). Approval was typically granted for 
indications with therapeutic alternative where a response rate ≥ 10% was demon-
strated. This research aims to define the circumstances under which oncologics 
can obtain both regulatory approval and public reimbursement in Australia on this 
basis. Methods: Public Summary Documents (PSDs) were extracted for any onco-
logic indication appraised by the FDA on pivotal Phase II data and the Therapeutic 
Goods Administration (TGA) and Pharmaceutical Benefits Advisory Committee 
(PBAC) decision and key rationale were extracted. Results: 3 oncologics across 7 
oncology indications (nilotinib in chronic myelogenous leukemia, dasatinib in acute 
lymphoblastic leukaemia (ALL), imatinib in ALL, dermatofibrosarcoma protuberans, 
myelodysplastic syndrome/ myeloproliferative disease and hypereosinophilic syn-
drome and/or chronic eosinophilic leukemia, and aggressive mastocytosis) have 
been granted TGA and PBAC approval on pivotal Phase II data. 2 were TGA approved 
but PBAC rejected (bevacizumab and cetuximab), 3 were submitted to PBAC on 
Phase III data, and no PSDs were extractable for the remaining 26 indications. In 
7/7 approved indications, PBAC recognized active comparator alternatives. In 4/7, 
the rarity of these indications was cited as a key mitigating factor. For 2/7, overall 
survival (OS) data was presented that indicated potentially substantial OS benefits. 
In 1/7, a cost-minimisation argument was accepted against a recently approved 
comparator. Of the PBAC-rejected drugs, cetuximab raised key concerns over a lack 
of OS data, while significant trial comparability issues were expressed with beva-
cizumab. All PBAC-approved submissions included economic modelling on a cost/
benefit, not cost/QALY, approach. ConClusions: PBAC can recommend the reim-
bursement of oncologics that offer potentially substantial clinical benefits based 
on an indirect comparison of single arms trials with acceptable cost-effectiveness 
as demonstrated on a cost-benefit metric.
PCN48
QuaLitY CoNtroL of the huNgariaN NatioNWide mammograPhY 
sCreeNiNg Programme
Boncz I1, Endrei D1, Ágoston I1, Vajda R1, Csákvári T2, Kovács G3, Sebestyén A4
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3Széchenyi István 
University, Győr, Hungary, 4National Health Insurance Fund Administration, Pécs, Hungary
objeCtives: Organised, nationwide screening for breast cancer with mammogra-
phy in the age group 45-65 years with 2 years screening interval started in Hungary 
in January 2002. According to the Hungarian guideline on mammography screening, 
an accredited mammography screening centre should perform 10000 examinations 
annually. The aim of this study is to analyze the quality control indicators of this 
screening programme. Methods: The data derive from the financial database of 
the National Health Insurance Fund Administration (NHIFA) covering the period 
2002-2010 year. We analysed 3 selected years: 2002, 2005 and 2010. The main indica-
tor was the number of mammography screening examinations performed by the 
mammography screening centres. Results: The annual number of mammography 
examinations was 323537 in 2002, 247045 in 2005 and 242601 in 2010. The number 
of accredited mammography screening centres were 51 (2002), 41 (2005) and 40 
(2010). The average number of mammography examinations were 6344 (2002), 6025 
(2005) and 6065 (2010) per year. In 2002, 14 mammography centres performed 10000 
examinations in a range from 10314 to 25940. In 2005 only 4 mammography centres 
achieved more than 10000 examinations per year (range: 10294-17845). In 2010 again 
only 4 mammography centres achieved more than 10000 examinations per year 
(range: 10239-19259). ConClusions: Only a few number of mammography centres 
met the recommendation of the Hungarian mammography screening guideline 
and reached the target (10000 mammography examinations annually). Most of the 
mammography centres are not able to comply with professional guideline.
diaBetes/eNdoCriNe disorders – Clinical outcomes studies
PdB1
iNCretiN theraPY aNd risk of PaNCreatitis iN tYPe 2 diaBetes 
meLLitus: sYstematiC reVieW of raNdomized aNd NoN-raNdomized 
studies
Li L1, Shen JT2, Bala MM3, Busse JW4, Ebrahim S4, Vandvik PO5, Rios LP6, Malaga G7, Wong 
E8, Sohani Z4, Guyatt GH4, Sun X1
vitro dissolution study in three different solvents such as hydrochloric acid pH 1.5, 
artificial saliva pH 6.7 and saline phosphate buffer solution pH 7.4 respectively. And 
drug release from the in vitro dissolution study. Results: The result reveals that 
prepared formulation F6 shown maximum value. The ex vivo permeation studies 
of Fluconazole drug through porcine buccal mucous membrane were performed 
and the results shown that F6 formulation was the best formulation among the 
prepared mouth dissolving tablets. ConClusions: Thus, the prepared (F6 formula-
tion) mouth dissolving tablets had both local and systemic action and may be used 
for treating oropharyngeal and esophageal candidiasis (oral candidiasis) mainly as 
ulcer, burning sensation of buccal cavity particularly in premature infants, geriatric 
bed ridden patients, and patients with weak immune system caused by cancer 
treatment or diseases such as AIDS.
PCN44
time to reimBursemeNt for oNCoLogY ageNts from ema marketiNg 
authorizatioN to aifa aPProVaL as “C(NN)” CLass Versus. aifa 
aPProVaL as “a” or “h” CLass
Monoson L1, Martin de Bustamante MA2, Beckerman R1
1CBPartners, New York, NY, USA, 2CBPartners, San Francisco, CA, USA
objeCtives: The purpose of this study was to evaluate the reduction in average 
market entry timelines for oncology agents in Italy if approved by AIFA as “C(nn)” 
class (non-negotiated class under the 189/2012 law) as compared to “A” (fully reim-
bursed) / “H” (hospital reimbursement). Methods: For the purpose of this study, 
only the approval of the agents’ first indications were taken into consideration. 
Included in this study were C(nn) oncology agents approved between May 27, 2013 
and February 27, 2014 (aflibercept, pertuzumab, bosutinib, enzalutamide, vismo-
degib, pomalidomide, regorafenib, dabrafenib, infliximab, afatinib, radium Ra223 
dichloride, trastuzumab emtansine) and class “A” / “H” agents approved between May 
27, 2010 and December 2, 2013 (everolimus®, denosumab, pazopanib, cabazitaxel, 
denosumab, abiraterone, vemurafenib, vandetanib, axitinib). The average time to 
approval was calculated as the average difference between the date of issue of EMA 
marketing authorization and the determination date (“determina”) in the Italian 
“Gazzetta Ufficiale”. Results: The average time to reimbursement for oncology 
agents from EMA marketing authorization to AIFA approval as “C(nn)” class was 
estimated as 111.3±39.9 days (n= 12), while the average time to reimbursement as 
either “A” or “H” class was estimated as 428.3±109.0 days (n= 9). This represents a 
significantly faster approval process (unpaired t-test, p< 0.01), where on average, the 
C(nn) approval process is faster by 317 days. ConClusions: This study shows that 
time to reimbursement for oncology agents from EMA marketing authorization to 
AIFA approval is significantly expedited through the use of “C(nn)” classification, 
reducing market entry timelines by nearly a full year (317 days) compared to the 
regular “A” or “H” class approval process. Pharmaceutical companies seeking expe-
ditious market entry into Italy for a newly approved oncology therapy targeting an 
area of high unmet need should therefore consider applying for C(nn) class.
PCN45
CoVerage deCisioN frameWork iN asia PaCifiC: a Case studY of 
targeted CaNCer mediCiNes iN the treatmeNt of Breast CaNCer
Sruamsiri R1, Chaiyakunapruk N2, Leartsakulpanitch J3
1Naresuan University, muang, Thailand, 2Monash University Malaysia, Selangor, Malaysia, 
3Janssen Asia Pacific, Singapore
objeCtives: To optimize access to cancer therapy in Asia Pacific (AP) nowadays 
became challenging due to budget constraints. Different decisions were made due 
to individual context, health care system and evidence required to support the 
decision. This study reviewed coverage decisions made by government in AP using 
targeted cancer medicines as a case study. Methods: We selected 6 targeted cancer 
medicines recommended for breast cancer treatment based on the 2013 national 
comprehensive cancer network guidelines. Eight AP countries with different health 
coverage system were included to highlight the differences of health coverage sys-
tem on decisions: four reimbursement countries [Australia (AUS), South Korea (KE), 
Taiwan (TW) and Japan (JP)] and four partial reimbursement countries [Malaysia 
(MY), Thailand (TH),China (CN) and Hong Kong (HK)]. We identified data from mul-
tiple sources including “Pubmed”, government websites, payers and companies 
from inception till Jan 2014. We compared health coverage features, oncology cov-
erage list and evidence requirement for decision making. Based on HTA approach, 
six possible supporting factors were compared. They included burden of disease, 
clinical effectiveness, economic evaluation (EE), budget impact analysis (BIA), public 
health impact, ethical concern and availability of alternative treatments. Results: 
Efficacy and safety data were used as decision factors in all countries. AUS, KE, TW 
and TH considered both EE and BIA. AUS, KE and TH required local HTA evidence 
.Of six medicines, trastuzumab is now covered in most countries: AUS, MY, TW 
and KE. However, limited information is publicly available on evidence used in 
coverage decision in most countries except AUS where all factors except public 
health impact and ethical issue consideration are documented. ConClusions: 
Coverage decisions are affected by health care system and HTA evidence. Limited 
public documents related to coverage decisions are available. HTA system may lead 
to the development of explicit decision framework criteria for coverage decisions.
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the iNCideNCe, PreVaLeNCe, aNd surViVaL of maLigNaNt meLaNoma iN 
taiWaN
Chang HY1, Feng HL1, Wang L2, Chou P2, Wang PF3
1National Health Research Institutes, Maoli county, Taiwan, 2Bristol-Myers Squibb, Taipei, Taiwan, 
3Bristol-Myers Squibb, Lawrenceville, NJ, USA
objeCtives: To understand the incidence, prevalence, and survival probability in 
the whole population in Taiwan. Methods: This study utilized the 2005 to 2011 
National Health Insurance (NHI) Research Database to study the disease. Inclusion 
criterion was that patients had at least two outpatient visits or one inpatient stay for 
melanoma (ICD9 code: 172). Patients’ medical orders for outpatient visits and inpa-
